These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 26447897)
21. Evaluating the utility of trefoil factor 1 as a mammary-specific immunostain compared and in conjunction with GATA-3 and mammaglobin in the distinction between carcinoma of breast and lung. Wells JM; Ginter PS; Liu Y; Chen Z; Narula N; Shin SJ Am J Clin Pathol; 2015 Sep; 144(3):444-51. PubMed ID: 26276775 [TBL] [Abstract][Full Text] [Related]
22. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Fritzsche FR; Thomas A; Winzer KJ; Beyer B; Dankof A; Bellach J; Dahl E; Dietel M; Kristiansen G Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung. Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644 [TBL] [Abstract][Full Text] [Related]
24. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology. Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030 [TBL] [Abstract][Full Text] [Related]
25. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583 [TBL] [Abstract][Full Text] [Related]
26. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin. Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362 [TBL] [Abstract][Full Text] [Related]
27. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin. Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444 [TBL] [Abstract][Full Text] [Related]
28. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes. Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285 [TBL] [Abstract][Full Text] [Related]
29. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Yang M; Nonaka D Mod Pathol; 2010 May; 23(5):654-61. PubMed ID: 20173733 [TBL] [Abstract][Full Text] [Related]
30. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249 [TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Yan Z; Gidley J; Horton D; Roberson J; Eltoum IE; Chhieng DC Diagn Cytopathol; 2009 Jul; 37(7):475-8. PubMed ID: 19217055 [TBL] [Abstract][Full Text] [Related]
32. Are mammaglobin and GCDFP-15 sensitive markers for diagnosis of metastatic basal-like triple negative breast carcinomas? Rakhshanı N; Daryakar A Turk Patoloji Derg; 2014; 30(1):18-22. PubMed ID: 24272937 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746 [TBL] [Abstract][Full Text] [Related]
34. A comparative immunohistochemistry study of diagnostic tools in salivary gland tumors: usefulness of mammaglobin, gross cystic disease fluid protein 15, and p63 cytoplasmic staining for the diagnosis of mammary analog secretory carcinoma? Projetti F; Lacroix-Triki M; Serrano E; Vergez S; Barres BH; Meilleroux J; Delisle MB; Uro-Coste E J Oral Pathol Med; 2015 Apr; 44(4):244-51. PubMed ID: 25040635 [TBL] [Abstract][Full Text] [Related]
35. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma. Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280 [TBL] [Abstract][Full Text] [Related]
36. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens. Braxton DR; Cohen C; Siddiqui MT Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841 [TBL] [Abstract][Full Text] [Related]
37. Cytokeratin 7: a re-evaluation of the 'tried and true' in triple-negative breast cancers. Davion SM; Siziopikou KP; Sullivan ME Histopathology; 2012 Oct; 61(4):660-6. PubMed ID: 22748158 [TBL] [Abstract][Full Text] [Related]
38. Preferential expression of NY-BR-1 and GATA-3 in male breast cancer. Biserni GB; Di Oto E; Moskovszky LE; Foschini MP; Varga Z J Cancer Res Clin Oncol; 2018 Feb; 144(2):199-204. PubMed ID: 29116378 [TBL] [Abstract][Full Text] [Related]
39. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Wang LJ; Greaves WO; Sabo E; Noble L; Tavares R; Ng T; DeLellis RA; Resnick MB Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):505-11. PubMed ID: 19620839 [TBL] [Abstract][Full Text] [Related]
40. Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study. El Hag MI; Hag AM; Ha JP; Michael CW Pleura Peritoneum; 2017 Sep; 2(3):143-148. PubMed ID: 30911644 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]